ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Prepare-NS. Welcome to Prepare-NS. https://www.prepare-ns.org/
-
2.
US Food and Drug Administration. CDER pilot grant program: Standard core clinical outcome assessments (COAs) and their related endpoints. January 18, 2022. https://www.fda.gov/drugs/development-approval-process-drugs/cder-pilot-grant-program-standard-core-clinical-outcome-assessments-coas-and-their-related-endpoints
-
3.
Cara Therapeutics. GlobeNewswire. Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. August 23, 2021. https://www.globenewswire.com/news-release/2021/08/23/2285085/0/en/Cara-Therapeutics-and-Vifor-Pharma-announce-U-S-FDA-approval-of-KORSUVA-difelikefalin-injection-for-the-treatment-of-moderate-to-severe-pruritus-in-hemodialysis-patients.html
-
4.
Fishbane S, et al. KALM-1 Trial Investigators. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med 2020; 382:222–232. doi: 10.1056/NEJMoa1912770
-
5.
Standardised Outcomes in Nephrology (SONG). The SONG Initiative. https://songinitiative.org/
Patient Experience Is Driving the Development of New Outcomes for Fluid Overload Treatment
Bridget M. Kuehn
Bridget M. Kuehn
Search for other papers by Bridget M. Kuehn in
Current site
Google Scholar
PubMed
Search for other papers by Bridget M. Kuehn in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory
Powered by PubFactory